

INNOVATION IN ACTION

Michel Goldman, Executive Director
Innovative Medicines Initiative (IMI)

Joint Exhibition

30 September - 4 October 2013



JOINT
TECHNOLOGY
INITIATIVES



fuel cells & hydrogen for sustainability




Innovative Medicines Initiative

Key messages


1. IMI contributes to quality of life in Europe
2. IMI contributes to the competitiveness of the European life sciences sector
3. IMI contributes to sharing of data and information

The diverse IMI community



Collective intelligence networks
Improved R&D productivity of pharma industries
Innovative approaches for unmet public health needs


IMI tackles diverse research areas



Brain disorders: a challenge for Europe

1 in 3

Europeans affected



€798 bn

costs to economy / year

Developing new drugs
**takes longer &
costs more**

than for other diseases

Sharing data to improve clinical trials for schizophrenia

23 000 patients

67 studies

25 countries




1 **newEds**
database

By **redesigning clinical trials**, you could:

- make them **shorter** (6 weeks → 4 weeks)
- require **fewer people** (79 → 46 patients per arm)
- **cut costs** (savings of €2.8 million)
- gain **insights** into effects of treatment on negative symptoms (e.g. lack of emotion)

Autism – a common disorder


- Affects 1 in 110
- Lifelong condition
- Difficulties in **social interaction & communication, unusual repetitive behaviours**
- Major impact on **families & carers**



Treatments designed specifically for autism

EU-AIMS – European action on autism

- New insights into underlying causes
- Could the brain changes be reversed?
- 2 major clinical trials for early detection and monitoring of ASD in children
- Working with regulators on treatment guidelines



Antimicrobial resistance: a growing threat

25 000

Europeans killed / year



€1.5 bn

costs to economy / year

2 new classes of antibiotics
in the last 30 years

IMI – New Drugs for Bad Bugs


- €229 million budget
- **Scientific challenges**
- **New models of collaboration**
- **Regulatory environment**
- **Incentives for industry to reinvest in the area**
- **Clinical trials network: 261 clinical sites in 32 countries**

IMI: a partner for SMEs

- IMIDIA generated the first human pancreatic beta cell line – a major breakthrough in diabetes research
- A French SME was at the heart of the research



‘Thanks to this collaboration, the robustness of our beta cells has been validated by large pharma companies – a major advantage for a biotechnology company like Endocells.’

– Anne-Fabienne Weitsch, CEO of Endocells



IMI contributes to drug safety

- SAFE-T project
 - 153 potential biomarker candidates for drug-induced injury of kidney, liver and vascular system evaluated
 - 17 exploratory clinical studies started or completed
 - Dialogue with regulatory agencies



IMI – joining forces for drug discovery

European Lead Factory

- An industry-like lead discovery platform available for public projects
- Joint European Compound Collection (Scotland)
 - 300 000 compounds from industry partners - in place ✓
 - 200 000 compounds from public partners
- European Screening Centre (the Netherlands)
 - 1st screen completed successfully ✓
- Sustainable model to establish independent business entity

IMI – putting patients at the heart of drug development

- U-BIOPRED – towards personalised medicine for severe asthma
- The challenge – to recruit 1 025 people
- Patients involved in project as partners & through ethics board, safety monitoring board, and patient input platform
- Offered patients' perspective on recruitment, study design, and project communication





INNOVATION IN *ACTION*

Joint Exhibition
30 September - 4 October 2013

THANK YOU!

www.imi.europa.eu

Twitter: @IMI_JU

JOINT
TECHNOLOGY
INITIATIVES



fuel cells & hydrogen for sustainability



Innovative Medicines Initiative